Endocrinology
Congress Materials
As part of our commitment to addressing unmet medical needs, Corcept investigates approved products and pipeline compounds and indications. Corcept presents its research at major congress events globally.
The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. The safety and efficacy of investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the US Food and Drug Administration or other regulatory authorities.
Access Corcept congress presentations below.
Filter by:
Annual Meeting of The Endocrine Society
2018
Administration of localized progestin before mifepristone treatment may prevent endometrial thickening and breakthrough bleeding
O’Dea JP, Lin PJ
Annual Meeting of The Endocrine Society
2018
Combining amiloride and spironolactone to manage hypokalemia and edema in patients with Cushing syndrome being treated with mifepristone
Cheng J, Bunta RL, Haider A
Annual Meeting of The Endocrine Society
2018
FKBP5 gene expression biomarker in ACTH-dependent Cushing syndrome patients pre- and postsurgery
Bancos I, Hatipoglu BA, Ji Yuen KC, Moriatis A
American Association of Clinical Endocrinology
2018
Phenotypic and metabolic improvements in a patient with equivocal findings of hypercortisolism treated with mifepristone: photographic and radiographic evidence
Thomas MJ, Smith JJ
American Association of Clinical Endocrinology
2018
Marked improvement in metabolic parameters in a patient with ACTH-independent hypercortisolism while on mifepristone
Ray R, Bunta R, Dauphin P
American Association of Clinical Endocrinology
2018
Mifepristone decreased the use of concentrated u500 insulin in patients with endogenous hypercortisolism who have type 2 diabetes mellitus
Mathews JW, Smith JJ
American Association of Clinical Endocrinology
2018
Open-label phase 2 study to assess safety and efficacy of relacorilant (cort125134), a selective cortisol modulator, in the treatment of endogenous hypercortisolism
Moraitis AG, Agrawal N, Bancos I, Celo FS, Gordon MB, Kargi AY, Lerman S, Mariash CN, Silverstein JM, Weirman ME
American Association of Clinical Endocrinology
2017
Mifepristone reduced u500 insulin usage in a patient with Cushing disease and normalized concomitant fatty liver disease and retinopathy
Bourne KA, Smith JJ
American Association of Clinical Endocrinology
2017
Screening of diabetic patients using u500 insulin uncovers a high percentage of undiagnosed hypercortisolism consistent with Cushing syndrome
Mathews JW, Smith JJ
American Association of Clinical Endocrinology
2017
Improving glycemic control with mifepristone in Cushing syndrome patients may lead to significant weight-loss
Ioachimescu AG, Ownby JG, Greyshock NG, Jones TC, Wand GS, Smith JJ
American Association of Clinical Endocrinology
2017
Mifepristone therapy significantly improved insulin resistance, glycemic control, and weight loss in a patient with Cushing disease previously treated with pasireotide
Ownby JG, Smith JJ
American Association of Clinical Endocrinology
2017
Medical management of mild hypercortisolism and primary aldosteronism in a patient with ACTH-independent macronodular hyperplasia presenting with resistant hypertension
Galati SJ, Lamerson M
American Association of Clinical Endocrinology
2017
Successful medical management with mifepristone in a patient with occult ectopic Cushing syndrome
Farghani S, Lamerson M
Annual Meeting of The Endocrine Society
2017
Mifepristone Treatment Effectively Improved Clinical Symptoms of Severe Hypercortisolism in a Patient With Primary Macronodular Adrenal Hyperplasia (PMAH) Allowing Surgical Treatment and Subsequent Conception
Mercado JU, Moloney K, Lim PJ, Yuen KCJ
Annual Meeting of The Endocrine Society
2017
A Case for Avoiding Unwarranted Surgery: A Patient with Primary Macronodular Adrenal Hyperplasia (PMAH) Initially Presenting as a Unilateral Adrenal Incidentaloma
Cohan P, Lim PJ, Peters AL
American Association of Clinical Endocrinology
2016
Immediate and sustained improvements in a cushing’s syndrome patient with primary macronodular adrenal hyperplasia treated with mifepristone
East, HE, Nquyen D
American Association of Clinical Endocrinology
2016
Prevention of secondary adrenal insufficiency with presurgical use of mifepristone in patients with autonomous cortisol-secreting adenomas
Parker JC, Smith JJ
Annual Meeting of The Endocrine Society
2016
Short-Term Mifepristone Treatment Improved Preoperative Clinical Status in a High-Risk Patient With Unexpected Normalization of Liver Enzymes
Andzel G, Thi Lam HN, Lim PJ
Annual Meeting of The Endocrine Society
2016
Cushing’s Syndrome Misdiagnosed as Bipolar Depression
Christofides EA, Pesa N, Nguyen D
Annual Meeting of The Endocrine Society
2016
Persistent Acromegaly Controlled on Pegvisomant with Co-Existing Non-ACTH Dependent Cushing’s Syndrome (CS) Due to Bilateral Adrenal Adenomas with Dramatic Clinical Response to Mifepristone
Gordon MB, Spiller KL, Bunta R, Gorden MS
Annual Meeting of The Endocrine Society
2016
No Incidence of Adrenal Insufficiency (AI) in Normo-cortisolemic Patients Treated With Mifepristone (MIFE): An Analysis of 5 Placebo-Controlled Clinical Trials
Cram D, Moraitis A, Nguyen D
Annual Meeting of The Endocrine Society
2015
Pre-surgical Use of Mifepristone for Ectopic Cushing’s in a High-Risk Bilateral Adrenalectomy Candidate
Madu IJ, Nguyen
Annual Meeting of The Endocrine Society
2015
Mifepristone for the Successful Treatment of Cushing’s Syndrome After Multiple Failed Interventions
Ijaz MT, Pesa N, Nguyen D
Annual Meeting of The Endocrine Society
2015
Marked Improvement in Liver Enzymes During Medical Therapy With Mifepristone for Cushing’s Syndrome
Ragucci E, Lamerson M
Annual Meeting of The Endocrine Society
2015
Treatment of Ectopic Cushing’s Syndrome With Mifepristone While Pending Tumor Localization
Rahnema MF, Chavez D, Nguyen D
American Association of Clinical Endocrinology
2015
Mifepristone Re-established Glycemic Control in a Cushing’s Syndrome Patient That Relapsed After a 21-Month Interruption
Frieze TW, Smith JJ
American Association of Clinical Endocrinology
2015
Resistant Metabolic Abnormalities Prompting Cushing’s Syndrome Work-up and Treatment With Mifepristone
Beatty DC, Bunta R, Nguyen D
American Association of Clinical Endocrinology
2015
Improved Response to Octreotide LAR for Ectopic Cushing’s Syndrome During Mifepristone Therapy: a Case Study
Moraitis A, Auchus RJ
American Association of Clinical Endocrinology
2015
Use of Mifepristone in an Ectopic Cushing’s Syndrome Patient Pending Tumor Localization
Ansari A, Lim P, Nguyen D
Annual Meeting of The Endocrine Society
2013
Quality of Life Changes in Participants of the SEISMIC Extension Trial in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
Adelman DT, Howell SM, Via PS
Annual Meeting of The Endocrine Society
2013
Using Mifepristone to Differentiate Cushing's Disease From Cushing's Syndrome
Ehrenkranz JRL, Gross C, Belanoff JK
Ehrenkranz JRL, Gross C, Belanoff JK
Annual Meeting of The Endocrine Society
2013
Endometrial Effects of Long-Term Mifepristone Treatment of Cushing's Syndrome: Results From the SEISMIC Studies
Carroll T, Ioffe O, Spitz IM, Gross C, Cram D, Hamrahian A
Auchus RJ, McPhaul MJ, Findling JW, Gross C
Katznelson L, Loriaux DL, Feldman D, et al